Empagliflozin and Cardiac Remodeling in Chronic Atrial Fibrillation
Jardiance (empagliflozin) does produce beneficial cardiac remodeling effects in heart failure patients with chronic atrial fibrillation, though the evidence specifically addresses left ventricular reverse remodeling in the context of heart failure rather than atrial fibrillation alone.
Evidence for Reverse Remodeling in HF Patients with Atrial Fibrillation
The EMPEROR-Preserved trial enrolled patients with heart failure and LVEF >40%, of whom 52% had baseline atrial fibrillation 1. Empagliflozin demonstrated consistent benefits in reducing cardiovascular death or HF hospitalization regardless of atrial fibrillation status (HR 0.78 in both AF and non-AF groups, interaction p=0.96) 1. While this trial established clinical efficacy, it did not specifically report structural remodeling parameters stratified by AF status.
Direct Evidence of Structural Remodeling
Recent comparative data from 2025 provides the most compelling evidence for empagliflozin's remodeling effects 2. In a 1-year study of 558 heart failure patients:
- Empagliflozin significantly reduced peak E-wave velocity (mean difference -12.76 cm/s, p<0.001)
- E/e' ratio decreased (mean difference -3.04, p<0.001), indicating improved diastolic function
- Left ventricular sphericity index improved (mean difference -0.01, p=0.040), suggesting favorable geometric remodeling
- Both empagliflozin and dapagliflozin reduced LAVI, LV-EDVI, LV-ESVI, LV-MI, and improved LVEF
These structural improvements occurred alongside clinical benefits, with empagliflozin showing more pronounced effects on certain remodeling markers compared to dapagliflozin 2.
Mechanism of Remodeling Benefits
The FDA label explains empagliflozin's mechanism: it reduces sodium reabsorption and increases distal tubule sodium delivery, which lowers both preload and afterload while downregulating sympathetic activity 3. These hemodynamic effects contribute to reverse remodeling.
Additional mechanistic data from 2025 demonstrates that empagliflozin reduces myocardial fibrosis through suppression of the TGF-β1/Smad3 signaling pathway, with collagen volume fraction decreasing from 25% to 12% in post-MI models 4. This anti-fibrotic effect is relevant to both ventricular and potentially atrial remodeling.
Acute Hemodynamic Effects
In acute heart failure, empagliflozin produces rapid improvements in cardiac loading conditions 5. After just 5 days of treatment:
- Left atrial volume decreased significantly (∆ = 30.9 ± 27.4 mL, p<0.001 vs placebo)
- Left atrial end-systolic volume index improved (∆ = 15.7 ± 15.1 mL/m², p=0.016 vs placebo)
These acute changes in left atrial parameters are particularly relevant for patients with chronic atrial fibrillation, as LA remodeling is central to AF pathophysiology.
Important Caveats and Clinical Context
The evidence for reverse remodeling is strongest in heart failure patients, not in isolated atrial fibrillation without heart failure. The 2022 AHA/ACC/HFSA guidelines recommend empagliflozin for HFpEF based on the EMPEROR-Preserved trial, which showed benefits regardless of AF status 6. However, guidelines note that benefits may be attenuated at LVEF >62.5% 6.
One critical limitation: the EMPRESS-MI trial (2025) found that empagliflozin did not prevent adverse remodeling in post-MI patients with reduced LVEF when added to contemporary standard care 7. LVESVI decreased similarly in both groups (between-group difference 0.3 mL/m², p=0.92), suggesting that in well-treated post-MI patients, additional remodeling benefits may be limited.
Clinical Recommendation Algorithm
For patients with chronic atrial fibrillation:
If heart failure is present (HFrEF or HFpEF): Initiate empagliflozin 10 mg daily as foundational therapy 6, 8. Expect reverse remodeling benefits including improved LV volumes, mass, and diastolic parameters over 6-12 months 2.
If no heart failure but cardiovascular disease/risk factors present: Consider empagliflozin for cardiorenal protection 8, though specific remodeling data in AF-only populations is lacking.
Monitor for: Volume depletion (especially in first week), genital mycotic infections, and ensure eGFR ≥20 mL/min/1.73 m² 3.
Optimize concurrent therapy: Continue guideline-directed medical therapy for both HF and AF. The remodeling benefits of empagliflozin are additive to standard treatments 8.
The reverse remodeling effects are clinically meaningful and translate to reduced HF hospitalizations and improved quality of life, making empagliflozin a priority medication for HF patients with concurrent chronic atrial fibrillation 6, 1.